Several studies have shown conflicting results with the use of intensive consolidation chemotherapy for breast cancer. The aim of the present study was to investigate the efficacy, feasibility and toxicity of high-dose chemotherapy with stem cell support in patients with high-risk stage II breast cancer. From February 1994 to November 1998, 132 consecutive patients with multinode positive breast cancer were entered to the study. In total, 86 patients had X10 positive axillary lymph nodes, and 46 had 4-9 positive axillary lymph nodes with at least two additional predetermined risk factors at diagnosis. All patients were offered adjuvant chemotherapy (doxorubicin, 75 mg/ m 2 Â 4) followed by high-dose chemotherapy (cyclophosphamide 6000 mg/m 2 , carboplatin 800 mg/m 2 and thiotepa 500 mg/m 2 ) and autologous stem cell support with growth factor. In all, 131 patients also received local radiation therapy and tamoxifen based on receptor status. After a median follow-up of 51 months (range 27-87), the disease-free and overall survival rates were 72 and 81%, respectively. There was no difference in the outcome for high-risk patients with 4 or o than 10 positive axillary lymph nodes. On Cox regression analysis only progesterone receptor status was predictive of disease-free, but not overall survival. There were no treatment-related deaths; grades III-IV toxicity was relatively low. This combined approach of doxorubicin followed by high-dose chemotherapy and stem-cell support, followed by locoregional radiotherapy, was safe and seems to be effective in patients with multinode positive stage II breast cancer. In previous trials of adjuvant high-dose therapy in this patient population, treatment-related morbidity and mortality markedly influenced the outcome. For this high-risk patient population, further testing of intensive chemotherapy regimens with a lower toxicity profile is warranted.
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Intensive consolidation chemotherapy is currently being investigated as a therapeutic option for aggressive, locally advanced breast cancer. To date results are controversial. Two prospective, randomized studies presented at the ASCO 2001 meeting showed no survival benefit.
1,2 The study by Peters et al 1 was impaired by the high incidence of treatment-related mortality in the high-dose arm, emphasizing the need for less toxic high-dose chemotherapy regimens in the adjuvant setting and for longer follow-up and more mature data. Gianni et al 2 used an unusual approach: very-short-term (o90 days) therapy consolidated by high-dose melphalan. An earlier report however, by Rodenhuis et al 3 (ASCO 2000) , noted promising results for high-dose chemotherapy in a similar setup, with a very low treatment-related mortality. Unfortunately, the different regimens used in the various studies, the small sample sizes, and the different staging techniques make comparisons difficult. The aim of the present prospective study was to investigate the efficacy, feasibility and toxicity of doxorubicin followed by intensive chemotherapy with stem-cell support in patients with high-risk stage II breast cancer with four or more positive axillary lymph nodes.
In view of the controversy surrounding this approach, this large prospective trial from a single center using a regimen with a low toxic profile may significantly contribute to the information regarding this high-risk group of patients.
Patients and methods (Table 1) In all, 132 consecutive patients with histologically proven American Joint Committee on Cancer (AJCC) 4 stage II breast carcinoma with high-risk factors who were treated at the Chaim Sheba Medical Center between January 1994 and October 1998 were entered into a prospective study of an intensive treatment protocol. The protocol was comprised of induction chemotherapy and high-dose chemotherapy with autologous stem-cell support, followed by locoregional radiotherapy; tamoxifen was administered on the basis of receptor status. The end points of the study were disease-free and overall survival in addition to shortand long-term transplant-related toxicity. The feasibility and toxicity of radiotherapy was previously described in Cancer.
5 High-risk stage II disease was defined as either X10 positive axillary lymph nodes (n ¼ 86/132, 60%) or 4-9 positive axillary lymph nodes (n ¼ 46/132, 40%) with two or more of the following poor prognostic features: age p35 years, histologic grade 3, less than 10 axillary lymph nodes sampled, tumor involvement of the axillary fat, or large tumor-involved axillary lymph nodes (42 cm). Other eligibility criteria were age p65 years and normal organ function, namely, normal radionuclide cardiac scan (multigated angiogram (at rest and exercise) 450%), carbon monoxide diffusing capacity of the lungs (DL) 460%, creatinine clearance 460 ml/min and normal liver function tests. All patients had a negative metastatic work-up that included brain, chest, abdominal and pelvic computed tomography scans; a normal radionuclide bone scan and normal findings on bilateral bone marrow biopsies (hematoxylin and eosin stain). Written informed consent was obtained from all patients.
The protocol specified adjuvant chemotherapy with a doxorubicin-based regimen. Single-agent doxorubicin (75 mg/m 2 every 3 weeks for a total of four cycles) was the preferred regimen, used in 111 patients (84%). The remaining 21 patients (16%) received cyclophosphamide (500-600 mg/m 2 ), doxorubicin (50-60 mg/m 2 ) and 5-fluorouracil (500-600 mg/m 2 ) every 21 days (four to six cycles). Surgery, performed by different surgeons, included lumpectomy (60%) or mastectomy (40%) and axillary lymph node dissection.
At 3-5 weeks after the last cycle of adjuvant chemotherapy, autologous peripheral stem cells were collected after induction with granulocyte colony-stimulating factor (G-CSF) (Neupogen; Amgen Biologicals, Thousand Oaks, CA, USA), 5 mg/kg/day subcutaneously. The cells were collected on days +5 and +6, and also +7, if necessary. The amount of cells required for consolidation with highdose chemotherapy was 5 Â 10 8 mononuclear cells/kg and 2.5 Â 10 6 CD34-positive cells/kg. An aliquot of reserve stem cell was preserved and stored. Collection was adequate in all patients. All patients received high-dose chemotherapy with the Stamp V protocol as previously described. 6 In brief, cyclophosphamide (1500 mg/m 2 continuous infusion per day for a total of 96 h), thiotepa (125 mg/ m 2 continuous infusion per day for a total of 96 h) and carboplatin (200 mg/m 2 continuous infusion per day for a total of 96 h) were given on days À7 to À3. Stem cells were reinfused on day 0 and G-CSF was administered the same day (n ¼ 119 patients) and continued until engraftment (absolute neutrophil count 41000/ml) was achieved. In 13 patients, G-CSF was started on days +2, +4, +5 and +6 after stem-cell transplantation, as part of an ongoing protocol. Prophylactic oral quinolone was given from day À2. Antibacterial and antifungal treatment was added for neutropenic fever as per routine protocols. Antibiotic coverage was stopped on engraftment or after resolution of a documented bacterial/fungal infection. Patients underwent transfusion with irradiated red blood cells and platelets to maintain hemoglobin levels of greater than 8 g/dl and platelet counts of greater than 5000/ml. Continuous infusion of morphine was given for severe mucositis. Oral cultures for herpes were performed only for patients with mucositis. None of the patients received total parenteral nutrition. After discharge, no prophylactic antibiotic therapy was given.
Radiotherapy was planned after recovery from high-dose chemotherapy and within 70 days of stem cell transplant. The radiotherapy protocol used in our center, delivered to 72% of the patients, has been previously described. 5 In brief, 5040 cGy (180 cGy fractions, 5 per week) were delivered with a 6 MeV linear accelerator to the breast/chest wall through two opposed tangential fields. The supraclavicular and axillary areas were treated through an anterior field with the same doses and fractions. An additional boost of 1400 cGy (9-12 MeV electrons, 200 cGy fractions) was given by a direct electron field to the area of the primary disease to patients after lumpectomy (based on the surgical scar and information obtained from the patients). The remaining 28% of the patients were irradiated at the referring centers. Only one patient did not receive radiotherapy because of transplant-related lung injury.
Patients with hormone receptor-positive tumors were treated with tamoxifen (20 mg/day) for 5 years after completing radiotherapy.
Statistical analysis
Means and standard deviations were computed. Student's t-test was used for comparisons of continuous variables Table 1 Patients characteristics between the two groups (49 vs 4-9 positive axillary lymph nodes). Disease-free and overall survival curves for all patients were calculated using the Kaplan-Meier product limit method, applied from the day of transplant, as in transplant protocols. When multivariate Cox regression analysis was performed, the regression coefficients were estimated by maximum-likelihood criteria, and their difference was determined by Wald's test. All tests were performed using SPSS statistical analysis software version 10.
Results

Treatment toxicity
There were no treatment-related deaths. Toxicity was similar in patients with X10 positive axillary lymph nodes and patients with 4-9 positive axillary lymph nodes ( Table  2 ). The most common side effect of the STAMP V protocol was mucositis grade III, which occurred in 59 patients (45%) and was treated with a morphine drip for a median of 8 days (1-14 days). None of the patients received total parenteral nutrition. Acute (grade 4II) cardiac toxicity was noted in three patients and acute renal and liver toxicities in one patient each; all resolved completely within 3 months of transplantation. Severe lung toxicity including infection was seen in eight patients (6%) after transplantation. One patient had diffuse alveolar hemorrhage requiring respiratory intensive care support for 10 days. Her pulmonary function (pulmonary function tests including diffusion capacity) fully recovered 1 year after the transplant. Another patient suffered from pulmonary emboli during transplantation and was treated with heparin. The other six patients had infectious complications, mostly bacterial pneumonia.
Documented infections were noted in 15% of the transplant patients. Of these, 40% had Gram-positive bacteremia related to line infection and the other 60% had Gram-negative bacterial infections. In 32% of the patients, oral culture was positive for herpes.
Supportive care
The supportive care provided after transplantation is shown in Table 3 . All patients had grade IV bone marrow toxicity. The median duration of neutropenia was 9 days (range 5-15). Almost all patients (98%) required red blood cell transfusions (median 3 units, range 0-10), and 95% required platelet transfusions (median 12 units (two adult random donor pack), range 0-54). Single-donor platelets were given only for refractory patients. In addition, 95% of the patients received intravenous antibacterial antibiotics for febrile neutropenia, for a median of 7 days (range 0-20). Median hospitalization time was 20 days (range 16-42). There were no significant differences between the two highrisk groups in any of these parameters.
Radiotherapy
Of the 132 patients in the present sample, 96 received radiotherapy at our institution. Overall, early post-transplant radiotherapy was very effective for local control, well tolerated and safe, as previously described. 6 One patient who did not receive radiotherapy had diffuse alveolar hemorrhage peritransplantation and required prolonged ventilation. At 4 years after the transplant, she had a single bony lesion that was treated with radiotherapy (reported as relapse). Table 2 Acute transplant-related toxicity, grade >II Less than 5% of the patients had late clinical pneumonitis. All were treated with a 6 to 10-week course of steroids with complete functional recovery. In one patient, there was one relapse of pneumonitis, which responded completely to a second course of steroids. This patient continues to do well more than 5 years after transplantation.
4-9+ALN (N=46) 10+ALN (N=86) % of total (N=132) P-value
Late complications
After a median follow-up of 51 months (range 27-86 months), no events of late cardiac morbidity, secondary leukemia, myelodysplastic syndrome or other malignancy were noted in any of the 132 treated patients.
Outcome
All 132 patients were eligible for the final analysis. After a median follow-up of 51 months (range 27-87), the diseasefree and overall survival rates were 72 and 81%, respectively. The disease-free and overall survival rates were similar for the patients with 4-9 positive axillary lymph nodes and the patients with 10 or more positive axillary lymph nodes (P ¼ 0.19). Cox regression analysis was performed to evaluate the predictive power of several prognostic features on the outcome. The number of positive nodes, status of estrogen receptor, type of surgery, young age, regimen of induction chemotherapy and number of chemotherapy cycles pre high-dose therapy were not predictive for disease-free and overall survival. Only progesterone receptor status was predictive of diseasefree, but not overall survival (Figures 1 and 2) .
The sites of first relapse after high-dose chemotherapy were liver 9% (n ¼ 12), bone 8% (n ¼ 10), lung 4% (n ¼ 5), brain 3% (n ¼ 4), chest wall 2% (n ¼ 3), lymph nodes 1% (n ¼ 2), peritoneum o1% (n ¼ 1), endometrium o1% (n ¼ 1), and cerebrospinal fluid o1% (n ¼ 1). In three patients, no data on site of first relapse were available. This pattern appears to be similar to that observed in patients treated with conventional chemotherapy.
Discussion
The results of the present study indicate that for patients with multinode positive stage II breast carcinoma, adjuvant chemotherapy followed by high-dose chemotherapy and autologous stem cell transplantation is feasible and safe. Further, the patient outcome is promising. After a median follow-up of 51 months from the end of therapy (range 27-86), the actuarial disease-free survival is 72% and the overall survival 81%.
As compared with conventional-dose chemotherapy, high-dose chemotherapy is believed to increase tumor cell kill. In the adjuvant setting, it may improve the chance of eradicating micrometastases in patients at high risk of relapse, thus increasing the impact of adjuvant therapy on survival.
Several phase II trials 7, 8 have reported encouraging results with intensive chemotherapy and autologous stemcell support, showing 60-75% progression-free and overall survival rates. Other studies, however, presented in abstract form at the 2001 meeting of the American Society of Clinical Oncology, failed to confirm these findings. 1, 2 In a large CALGB trial, Peters et al 1 compared the survival of patients treated with adjuvant CAF followed by a highdose STAMP I regimen (cyclophosphamide, cisplatin and carmustine) and PSC support, and patients given the same induction chemotherapy followed by a low-dose similar transplanted groups. There was no statistical difference in DFS in the two groups of patients (P ¼ 0.189).
Stem cell transplant for hight risk stage II breast cancer SM Stemmer et al regimen. At a median follow-up of 5.1 years, the intent-totreat event-free survival was 61% for the patients given the high-dose regimen and 60% for the low-dose BCNU regimen. Although the transplant group had fewer relapses (28.9 vs 39.1%), there were 32 transplant-related deaths, as opposed to none in the control group. At 5 years, overall survival in the two groups was 70 and 72%, respectively. The authors concluded that for this patient population the overall outcome exceeded that of studies with standarddose therapy alone, but there were no significant differences in either event-free or overall survival between the highdose regimen (transplant) and the low-dose regimen (control). Nevertheless, the high transplant-related mortality of 7.4% (6% in an experienced center and 11% in inexperienced centers) renders these results too premature for interpretation, even after 5 years of follow-up. Gianni and Bonadonna 2 compared a non-crossresistant chemotherapy regimen delivered over a very short period of time, with the classical doxorubicin regimen followed by CMF. After a median follow-up of 52 months, the 5-year progression-free survival rates were 65% in the transplant group and 62% in the conventionally treated group. The overall survival rates were 76 and 77%, respectively. However, when the 112 patients younger than 36 years and the 147 patients with 4-9 positive lymph nodes were considered separately, those who received the high-dose regimen had a trend towards an improved progression-free survival. It is possible that the very short-term therapy, known to be less effective than longer therapy, 9 delivered in the high-dose arm (o90 days) was inadequate for the veryhigh-risk population (410 positive axillary lymph nodes), but sufficient for the intermediate-high-risk population (4-9 positive axillary lymph nodes).
An initial analysis by a Dutch group 3 of 284 patients randomized to receive either high-dose chemotherapy with autologous stem cell support or conventional chemotherapy showed a statistical benefit in the high-dose arm with regard to disease-free survival, and borderline significant improvement in overall survival. Similar results were reported by a French 10 group. Both studies reported very low rates of treatment-related mortality.
The length of follow-up in our study was similar to that reported by Peters et al, 1 Gianni 2 and Rodenhuis et al, 3 and like the latter two studies, we had no treatment-related mortality. The duration of therapy as well as the transplant protocol used here were similar to those used by Rodenhuis et al 3 and we report of a similar disease-free survival of 70% and overall survival of more than 80%.
Studies with high-dose chemotherapy that carry a high transplant-related mortality should be interpreted carefully when follow-up is relatively short. The longer the followup, the less the impact of treatment-related mortality on overall survival. Thus, initial reports from the Parma study of high-dose chemotherapy for non-Hodgkin's lymphoma showed similar survival for the transplant and conventional arms, 11 and the benefit of transplantation became clear only after a longer follow-up.
The absence of mortality in our series reflects stringent patient selection, patient care by a single experienced team in one hospital, selection of a noncarmustine-based transplant protocol, and the use of peripheral blood stemcell support. This is in line with other studies showing a marked reduction in transplant-related mortality when using peripheral stem-cell support. 12 With regard to the specific role of the adjuvant regimen in these trials Rodenhuis et al, 3 Hortobagyi, 13,14 Gianni and Bonadonna, 2 and Peters et al, 1 used a cyclophosphamidebased protocol for induction, which theoretically could have induced resistance to a high-dose cyclophosphamidecontaining transplant protocol. We elected to use singleagent doxorubicin as adjuvant chemotherapy, followed by a high-dose alkylating protocol as consolidation. We failed to show that patients treated with doxorubicin alone did better than patients who received CAF. Nevertheless, this was not the aim of this study, and the two groups (84% of patients who received single-agent doxorubicin vs 16% who received CAF) were too small for statistical analysis.
No difference was found in disease-free and overall survival between the two high-risk groups: patients with X10 positive axillary lymph nodes, and those with 4-9 positive axillary lymph nodes and other poor prognostic features. Our results for patients in the 4-9 axillary lymph node subgroup were similar to those of Bearman et al, 15 who achieved a 71% disease-free survival after a median follow-up of 31 months.
Marks et al 16 reported that patients with high-risk breast carcinoma treated with high-dose chemotherapy and autologous bone marrow transplantation had a significant incidence of locoregional recurrence when locoregional irradiation was omitted. To obtain the maximum benefit from locoregional radiotherapy, it is important to ensure that it is safe and has a minimal risk of long-term morbidity, particularly when it follows chemotherapy, which is expected to increase treatment-related morbidity. The high-dose carmustine protocol used by Peters et al, 1 is known to cause severe lung injury in more than 40% of patients. The lung injury precluded the early initiation of radiotherapy in the transplant arm. Thus, only 78% of the patients allocated to the transplant arm received radiotherapy compared to 89% in the control arm. 17 This may explain in part the nonsignificant findings in disease free and survival in Peters study. 1 In our study, the low rate of lung injury (o5%), probably because of a noncarmustinebased transplant protocol, enabled initiation of radiotherapy as scheduled. In all, 99% of patients were given radiation therapy with minimal radiation-related toxicity, because of a strict radiation procedure keeping lung volume to a minimum.
Cox multivariate analysis demonstrates that only progesterone receptor status was an independent predictor of disease-free survival, but not overall survival. These data are in agreement with Somlo et al, 18 who found PR to be a predictor of overall survival as well.
The issue of stem cell contamination by breast cancer cells and the effect of purging were not addressed in this report. Nevertheless, one inclusion criterion for the study was negative bilateral bone marrow biopsies with hematoxylin-eosin staining. One preliminary report has shown a possible reduction in relapse in patients with CD34 positive stem-cell transplantation. 19 This study is one of the largest single-institution series with prolonged follow-up (median of 51 months) reported in the literature. Our results compare favorably with results using conventional-dose adjuvant chemotherapy with a median follow-up of 3-10 years (20-60% disease-free survival). 20, 21 Although such comparisons need to be conducted carefully because of differences in patient selection, supportive care, and other. In summary, patients with intermediate and high-risk stage II breast cancer consolidated with high-dose chemotherapy and autologous stem cell transplantation had an actuarial disease-free survival of 72% and an overall survival of 81% after a median follow-up of 51 months from transplantation. On the basis of these findings, we believe that intensive chemotherapy with stem cell support may play a role in the comprehensive treatment of this patient population. Further studies are needed to reach a definite conclusion.
